News

UPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
July 28, 2020
BerGenBio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib…
Read More
BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB
July 20, 2020
Bergen, Norway, 20 July 2020 –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN checkpoint inhibitor refractory NSCLC PATIENTS
June 25, 2020
6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical benefit 12 evaluable patients for cAXL…
Read More
BERGENBIO ANNOUNCES CHANGE TO PRESENTATION TIME AT Next Gen Immuno-Oncology Congress
June 24, 2020
Bergen, Norway, 24 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020
June 23, 2020
Bergen, Norway, June 23, 2020 – BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…
Read More
BERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT Next Gen Immuno-Oncology Congress
June 15, 2020
Bergen, Norway, 15 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More- Previous
- Go to page 1
- Go to page 2
- Go to page 3
- Go to page 4
- Interim pages omitted …
- Go to page 29
- NEXT